MX2021004173A - Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. - Google Patents
Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.Info
- Publication number
- MX2021004173A MX2021004173A MX2021004173A MX2021004173A MX2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- staphylococcus aureus
- protein
- aureus antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743490P | 2018-10-09 | 2018-10-09 | |
| US201962833297P | 2019-04-12 | 2019-04-12 | |
| PCT/US2019/055143 WO2020076789A2 (en) | 2018-10-09 | 2019-10-08 | Combinations of anti-staphylococcus aureus antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004173A true MX2021004173A (es) | 2021-09-08 |
Family
ID=70051346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004173A MX2021004173A (es) | 2018-10-09 | 2019-10-08 | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11168133B2 (https=) |
| EP (1) | EP3864041A2 (https=) |
| JP (1) | JP2022512647A (https=) |
| KR (1) | KR20210072057A (https=) |
| CN (1) | CN113164602A (https=) |
| AU (1) | AU2019357983A1 (https=) |
| BR (1) | BR112021006622A2 (https=) |
| CA (1) | CA3115633A1 (https=) |
| MX (1) | MX2021004173A (https=) |
| TW (1) | TW202035443A (https=) |
| WO (1) | WO2020076789A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375324B (es) * | 2012-11-06 | 2025-03-06 | Medimmune Llc | Anticuerpos contra determinantes de la superficie de s. aureus. |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| CN113811544A (zh) | 2019-03-13 | 2021-12-17 | 免疫医疗有限责任公司 | 减少定殖患者中的金黄色葡萄球菌感染 |
| WO2021225912A1 (en) * | 2020-05-07 | 2021-11-11 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
| CN117771379B (zh) * | 2023-10-25 | 2024-08-30 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1377314E (pt) | 2001-01-26 | 2012-01-02 | Inhibitex Inc | Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| EP1479695B1 (en) | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| EP2043690A1 (en) | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| ES2650224T3 (es) | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Proteínas de unión al antígeno C-FMS humano |
| EP2185190B1 (en) | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| CN102171247A (zh) | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| RU2677140C1 (ru) | 2010-05-05 | 2019-01-15 | Нью-Йорк Юниверсити | Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение |
| EP3470526A3 (en) | 2011-02-08 | 2019-07-17 | Medimmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| US9845348B2 (en) | 2012-11-06 | 2017-12-19 | Medimmune, Llc | Methods of treating S. aureus-associated diseases |
| MX375324B (es) | 2012-11-06 | 2025-03-06 | Medimmune Llc | Anticuerpos contra determinantes de la superficie de s. aureus. |
| EP3057989A1 (en) | 2013-10-17 | 2016-08-24 | ARSANIS Biosciences GmbH | Cross-reactive staphylococcus aureus antibody sequences |
| EP3142700B1 (en) | 2014-05-16 | 2021-03-03 | Medimmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| MX2017012775A (es) * | 2015-04-17 | 2019-04-29 | Arsanis Biosciences Gmbh | Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
-
2019
- 2019-10-08 CN CN201980078574.1A patent/CN113164602A/zh active Pending
- 2019-10-08 BR BR112021006622-5A patent/BR112021006622A2/pt not_active IP Right Cessation
- 2019-10-08 TW TW108136341A patent/TW202035443A/zh unknown
- 2019-10-08 US US16/596,388 patent/US11168133B2/en active Active
- 2019-10-08 WO PCT/US2019/055143 patent/WO2020076789A2/en not_active Ceased
- 2019-10-08 EP EP19871705.0A patent/EP3864041A2/en not_active Withdrawn
- 2019-10-08 AU AU2019357983A patent/AU2019357983A1/en not_active Abandoned
- 2019-10-08 MX MX2021004173A patent/MX2021004173A/es unknown
- 2019-10-08 CA CA3115633A patent/CA3115633A1/en active Pending
- 2019-10-08 KR KR1020217013653A patent/KR20210072057A/ko not_active Ceased
- 2019-10-08 JP JP2021519612A patent/JP2022512647A/ja not_active Ceased
-
2021
- 2021-10-01 US US17/491,889 patent/US20220089699A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220089699A1 (en) | 2022-03-24 |
| TW202035443A (zh) | 2020-10-01 |
| CA3115633A1 (en) | 2020-04-16 |
| BR112021006622A2 (pt) | 2021-07-20 |
| WO2020076789A2 (en) | 2020-04-16 |
| AU2019357983A1 (en) | 2021-05-27 |
| US11168133B2 (en) | 2021-11-09 |
| EP3864041A2 (en) | 2021-08-18 |
| KR20210072057A (ko) | 2021-06-16 |
| JP2022512647A (ja) | 2022-02-07 |
| CN113164602A (zh) | 2021-07-23 |
| WO2020076789A3 (en) | 2020-10-22 |
| US20200109189A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004173A (es) | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
| WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EP4374922A3 (en) | Anti-c5 antibodies and uses thereof | |
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| BR112016028043A2 (pt) | composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| EA201991643A1 (ru) | Человеческие антитела к токсину гемолизину а s.aureus | |
| PH12021550332A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| MX2021004114A (es) | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. | |
| PH12022551398A1 (en) | Anti-mertk antibodies and methods of use thereof | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
| WO2017075188A3 (en) | Methods of using anti-alpha toxin antibody | |
| EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
| EP3947447A4 (en) | ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY FOR THE TREATMENT OF TUMORS | |
| CL2023003331A1 (es) | Anticuerpos anti-tmprs66 y usos de los mismos. | |
| WO2019094533A8 (en) | Angptl8-binding agents and methods of use thereof | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. |